Substance use disorder providers caring for underserved populations could get a new boost in funding.
Opioid manufacturers, distributors and other entities involved with the opioid epidemic will pay $56 billion over the next 10 to 20 years for their role in the crisis. That’s broken into several different settlement agreements, the largest being the $26 billion settlement involving the three wholesalers AmerisourceBergen (NYSE: COR), Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK), as well as Johnson & Johnson (NYSE: JNJ). Today, only about $3 billion has been distributed.
“It’s not nothing, but we are still very much in the early innings with this funding,” Dr. Nasser Khan, operations group president for Acadia Healthcare’s (Nasdaq: ACHC) Comprehensive Treatment Center (CTC) division, told Behavioral Health Business. Read more.
